These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26231159)

  • 1. Discovery of Tyk2 inhibitors via the virtual site-directed fragment-based drug design.
    Jang WD; Kim JT; Son HY; Park SY; Cho YS; Koo TS; Lee H; Kang NS
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3947-52. PubMed ID: 26231159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.
    Norman P
    Expert Opin Ther Pat; 2012 Oct; 22(10):1233-49. PubMed ID: 22971156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1.
    Fensome A; Ambler CM; Arnold E; Banker ME; Clark JD; Dowty ME; Efremov IV; Flick A; Gerstenberger BS; Gifford RS; Gopalsamy A; Hegen M; Jussif J; Limburg DC; Lin TH; Pierce BS; Sharma R; Trujillo JI; Vajdos FF; Vincent F; Wan ZK; Xing L; Yang X; Yang X
    Bioorg Med Chem; 2020 May; 28(10):115481. PubMed ID: 32253095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.
    Malerich JP; Lam JS; Hart B; Fine RM; Klebansky B; Tanga MJ; D'Andrea A
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7454-7. PubMed ID: 21106455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of selective TYK2 inhibitors: Design, synthesis, in vitro and in silico studies of promising hits with triazolopyrimidinone scaffold.
    Istanbullu H; Coban G; Turunc E; Disel C; Debelec Butuner B
    Bioorg Chem; 2024 Jul; 148():107430. PubMed ID: 38728909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-Based Design and Synthesis of 3-Amino-1,5-dihydro-4H-pyrazolopyridin-4-one Derivatives as Tyrosine Kinase 2 Inhibitors.
    Yogo T; Nagamiya H; Seto M; Sasaki S; Shih-Chung H; Ohba Y; Tokunaga N; Lee GN; Rhim CY; Yoon CH; Cho SY; Skene R; Yamamoto S; Satou Y; Kuno M; Miyazaki T; Nakagawa H; Okabe A; Marui S; Aso K; Yoshida M
    J Med Chem; 2016 Jan; 59(2):733-49. PubMed ID: 26701356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of a peptide inhibitor of tyrosine kinase 2.
    Works MG; Song B; Kibler P; Tanga MJ; Galande AK; D'Andrea A
    Protein Pept Lett; 2014 May; 21(5):419-25. PubMed ID: 24304386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model.
    Liang J; Van Abbema A; Balazs M; Barrett K; Berezhkovsky L; Blair WS; Chang C; Delarosa D; DeVoss J; Driscoll J; Eigenbrot C; Goodacre S; Ghilardi N; MacLeod C; Johnson A; Bir Kohli P; Lai Y; Lin Z; Mantik P; Menghrajani K; Nguyen H; Peng I; Sambrone A; Shia S; Smith J; Sohn S; Tsui V; Ultsch M; Williams K; Wu LC; Yang W; Zhang B; Magnuson S
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4370-4376. PubMed ID: 28830649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lead identification of novel and selective TYK2 inhibitors.
    Liang J; Tsui V; Van Abbema A; Bao L; Barrett K; Beresini M; Berezhkovskiy L; Blair WS; Chang C; Driscoll J; Eigenbrot C; Ghilardi N; Gibbons P; Halladay J; Johnson A; Kohli PB; Lai Y; Liimatta M; Mantik P; Menghrajani K; Murray J; Sambrone A; Xiao Y; Shia S; Shin Y; Smith J; Sohn S; Stanley M; Ultsch M; Zhang B; Wu LC; Magnuson S
    Eur J Med Chem; 2013 Sep; 67():175-87. PubMed ID: 23867602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease.
    Yang T; Cui X; Tang M; Qi W; Zhu Z; Shi M; Yang L; Pei H; Zhang W; Xie L; Xu Y; Yang Z; Chen L
    J Med Chem; 2022 Feb; 65(4):3151-3172. PubMed ID: 35113547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases.
    Gerstenberger BS; Ambler C; Arnold EP; Banker ME; Brown MF; Clark JD; Dermenci A; Dowty ME; Fensome A; Fish S; Hayward MM; Hegen M; Hollingshead BD; Knafels JD; Lin DW; Lin TH; Owen DR; Saiah E; Sharma R; Vajdos FF; Xing L; Yang X; Yang X; Wright SW
    J Med Chem; 2020 Nov; 63(22):13561-13577. PubMed ID: 32787094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).
    He X; Chen X; Zhang H; Xie T; Ye XY
    Expert Opin Ther Pat; 2019 Feb; 29(2):137-149. PubMed ID: 30621465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting TYK2 for Fighting Diseases: Recent Advance of TYK2 Inhibitors.
    Du SS; Fang YQ; Zhang W; Rao GW
    Curr Med Chem; 2024; 31(20):2900-2920. PubMed ID: 38904160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of WO2013125543, WO2013146963 and EP2634185: the first Tyk2 inhibitors from Takeda and Sareum.
    Norman P
    Expert Opin Ther Pat; 2014 Mar; 24(3):361-8. PubMed ID: 24386992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors.
    Hynes J; Wu H; Kempson J; Duan JJ; Lu Z; Jiang B; Stachura S; Tokarski JS; Sack JS; Khan JA; Lippy JS; Zhang RF; Pitt S; Shen G; Gillooly K; McIntyre K; Carter PH; Barrish JC; Nadler SG; Salter-Cid LM; Fura A; Schieven GL; Pitts WJ; Wrobleski ST
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3101-3106. PubMed ID: 28539220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of tyrosine kinase 2 in autoimmunity.
    Liang Y; Zhu Y; Xia Y; Peng H; Yang XK; Liu YY; Xu WD; Pan HF; Ye DQ
    Expert Opin Ther Targets; 2014 May; 18(5):571-80. PubMed ID: 24654603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor.
    Argiriadi MA; Goedken ER; Banach D; Borhani DW; Burchat A; Dixon RW; Marcotte D; Overmeyer G; Pivorunas V; Sadhukhan R; Sousa S; Moore NS; Tomlinson M; Voss J; Wang L; Wishart N; Woller K; Talanian RV
    BMC Struct Biol; 2012 Sep; 12():22. PubMed ID: 22995073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient synthesis of tert-butyl 3-cyano-3-cyclopropyl-2-oxopyrrolidine-4-carboxylates: Highly functionalized 2-pyrrolidinone enabling access to novel macrocyclic Tyk2 inhibitors.
    Sasaki Y; Tokuhara H; Ohba Y; Okabe A; Nakayama M; Nakagawa H; Skene R; Hoffman I; Zou H; Yoshida M
    Bioorg Med Chem Lett; 2020 Mar; 30(5):126963. PubMed ID: 31980341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences.
    Gerstenberger BS; Banker ME; Clark JD; Dowty ME; Fensome A; Gifford R; Griffor MC; Hegen M; Hollingshead BD; Knafels JD; Lin TH; Smith JF; Vajdos FF
    Sci Rep; 2020 Jun; 10(1):8974. PubMed ID: 32488071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2.
    Liu C; Lin J; Langevine C; Smith D; Li J; Tokarski JS; Khan J; Ruzanov M; Strnad J; Zupa-Fernandez A; Cheng L; Gillooly KM; Shuster D; Zhang Y; Thankappan A; McIntyre KW; Chaudhry C; Elzinga PA; Chiney M; Chimalakonda A; Lombardo LJ; Macor JE; Carter PH; Burke JR; Weinstein DS
    J Med Chem; 2021 Jan; 64(1):677-694. PubMed ID: 33370104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.